Generation Bio (NASDAQ:GBIO) Upgraded by Wall Street Zen to “Sell” Rating

Generation Bio (NASDAQ:GBIO) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Other research analysts have also recently issued reports about the company. Citigroup reaffirmed a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Wedbush set a $5.50 price target on shares of Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Finally, Zacks Research raised shares of Generation Bio to a “hold” rating in a report on Monday, January 26th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.88.

Generation Bio Stock Performance

Shares of GBIO opened at $5.34 on Friday. The company has a market cap of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05. The stock has a fifty day moving average price of $5.53 and a two-hundred day moving average price of $5.62. Generation Bio has a 52-week low of $3.00 and a 52-week high of $8.20.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in shares of Generation Bio during the 1st quarter worth approximately $36,000. Marshall Wace LLP acquired a new stake in Generation Bio during the 2nd quarter worth $37,000. Y Intercept Hong Kong Ltd acquired a new stake in Generation Bio during the 2nd quarter worth $47,000. Shay Capital LLC bought a new stake in shares of Generation Bio during the 3rd quarter valued at $64,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Generation Bio in the 3rd quarter valued at $136,000. Institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.